New trials activated in June and July

From the Cancer Clinical Trials Office (CCTO)

New trials activated in June and July

  1. LU209274   P. Stiff Phase I/II Study of dose escalated carfilzomib, busulfan and melphalan with autologous stem cell transplant for the treatment of patients with multiple myeloma

  2. LU210128   S. Smith   An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma (BGB-3111-212) 

  3.  LU210202  S. Smith A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1

  4. LU212057  S. Berg EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

  5. LU208066  J. Clark DREAMseq (Doublet, Randomized Evaluation in AdvancedMelanoma Sequencing) Trial. 

  6. LU211704   M. Harkenrider  Phase II Study of Concurrent and Sequential Carboplatin and Paclitaxel with Adjuvant Radiotherapy for High Risk Endometrial Cancer 

  7. LU209642   M. Harkenrider  EMBRACE-II: Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer (EMBRACE-II)

  8. LU210853   W. Small    Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared to Standard of Care (SAVE). 

  9. LU206949 P. Stiff     A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) KTE-C19-101